@prefix biolink: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix dct: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo .
}
sub:assertion {
biolink:category biolink:Disease .
sub:association a rdf:Statement;
rdf:object ;
rdf:predicate biolink:treats;
rdf:subject ;
rdfs:label "\"ORILISSA is contraindicated in women: Who are pregnant [see Use in Specific Populations ( 8.1 With known osteoporosis because of the risk of further bone loss [see Warnings and Precautions ( 5.1 With severe hepatic impairment [see Use in Specific Populations ( 8.7 12.3 With concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil) [see Drug Interactions ( 7.2 Pregnancy ( 4 Known osteoporosis ( 4 Severe hepatic impairment ( 4 Strong organic anion transporting polypeptide (OATP) 1B1 inhibitors ( 4\"";
biolink:provided_by ;
biolink:relation schema:MedicalContraindication .
biolink:category biolink:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "edrHP6jg06G2AtRoWIAYLdQD3o3l/CVCQyOIPCIAYJmN0BiUgLUd0WFNBAcsBI6b4f3GGV8BWr+m/aLmwhOwGQqfOJfoKtBBFHQ7NZCv677fvyW1X1duGwlCYMIgwiFxvCDOfKIUnBm1fTarng5YPnt9cPd7JGLC2gx0yovyEL0=";
npx:hasSignatureTarget this: .
this: dct:created "2021-08-25T14:03:22.564+02:00"^^xsd:dateTime;
dct:creator orcid:0000-0002-1468-3557;
ns1:wasCreatedFromProvenanceTemplate ;
ns1:wasCreatedFromPubinfoTemplate ;
ns1:wasCreatedFromTemplate .
}